Tizona Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tizona Therapeutics, Inc.
After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Deal snapshot: Gilead’s latest significant cancer deal brings it a CCR8 binder, a novel preclinical immunotherapy, while Jounce finds a new deep-pocketed partner after the termination of its collaboration with Celgene.
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.